Precision BioSciences, Inc. (DTIL) Stock Price & Analysis

Precision BioSciences, Inc. (DTIL) closed at USD 9.68 on Monday, November 9, 2026, down 8.68% on the day. The US market is currently closed; this is not a live price.

The prior close was USD 10.6; the Nov 9, 2026 session ranged USD 9.62–10.8 on volume of 589,692 shares. Market capitalization is $369.49M, with a 52-week range of USD 3.53–11.29 (NCM). Source: Nexqual, retrieved November 10, 2026 at 04:58 UTC.

Also available as compact Markdown for AI agents: nexqual.com/DTIL.md

Key facts (DTIL)

• Last four reported quarters (through Sep 30, 2026): revenue $45.0M, net income -$38.5M (-85.6% margin), free cash flow -$51.8M (SEC filings).
• Insider open-market purchases, last ~7 months: 3 Form 4 filings, $30K; 0 by opportunistic insiders, 0 by routine insiders.
• Analysts: Buy (mean 2.00 on a 1–5 scale) (5 analysts), mean target USD 29.4 (range 18–60).
• Total return with dividends: 1Y +59.5% vs S&P 500 +11.7%; 5Y -96.7% vs S&P 500 +72.2%.
• Latest earnings report: 2026-11-03 (next date not yet announced).
• Dividend: DTIL paid no cash dividend in the last five years.
• Short interest: 8.66% of float (as of 2026-10-15), 8.6 days to cover.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (DTIL)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Sep 30, 2026) (DTIL)

P/S 8.2x · P/B 7.1x · FCF yield -14.02% · Earnings yield -10.43%

P/E at fiscal year-ends: Dec 2024 3.7x.

Insider purchases (SEC Form 4, open-market, last ~7 months) (DTIL)

3 purchases, $30K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (DTIL)

Consensus Buy (mean 2.00 on a 1–5 scale), 5 analysts; mean target USD 29.4 (low 18, high 60).

Rating changes, last 120 days:

Total return (dividends reinvested) (DTIL)

Dividends (DTIL)

DTIL paid no cash dividend in the last five years.

Short interest (DTIL)

2,356,838 shares sold short, 8.66% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 2,223,477 shares (+6.0%). Days to cover: 8.6 (short shares ÷ average daily volume).

DTIL earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

DTIL recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

DTIL suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Mar 12, 2026.

Companies that name DTIL in their SEC reports

DTIL company outlook (results filed Nov 3, 2026)

• “Initial safety data are targeted for year-end 2026, with efficacy data at distinct timepoints expected to follow in H1 and H2 2027.”
• “The Company expects that existing cash and cash equivalents, continued fiscal and operating discipline, and availability of Precision's at-the-market facility will fund the Company's cash runway through 2028.”
• “Based on its expected cash runway, Precision projects it is sufficiently capitalized to achieve key PBGENE-HBV and PBGENE-DMD clinical data milestones through 2028.”
• “Revenues: As expected, no revenue was reported for the quarter ended September 30, 2026, compared to less than $0.1 million for the quarter ended September 30, 2025.”

Quoted word-for-word from the SEC 8-K results press release.

DTIL analyst estimates and revisions

DTIL options: expected move

30-day implied volatility 156.8% vs 97.1% realized over the last 30 trading days. Put/call ratio (volume) 0.79. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of November 10, 2026 at 04:58 UTC)

Technical Analysis (DTIL)

Nexqual's technical model rates DTIL "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of November 10, 2026 at 04:58 UTC.

Analyst Ratings (DTIL)

Wall Street analysts rate DTIL "Buy" based on 5 analysts, with a mean price target of USD 29.4 (range USD 18–60), per Nexqual as of November 10, 2026 at 04:58 UTC.

Earnings (DTIL)

Recent Earnings History

Source: Nexqual, November 10, 2026 at 04:58 UTC.

Financials & Fundamentals (DTIL)

Source: Nexqual, November 10, 2026 at 04:58 UTC.

Financial Health Score (DTIL)

Nexqual rates Precision BioSciences, Inc.'s overall financial health "Weak" across five dimensions, as of November 10, 2026 at 04:58 UTC.

Ownership (DTIL)

Source: Nexqual, November 10, 2026 at 04:58 UTC.

Leadership (DTIL)

Precision BioSciences, Inc. is led by Michael Amoroso, President, CEO & Director, per Nexqual as of November 10, 2026 at 04:58 UTC.

Major Backers & Investors (DTIL)

Notable institutional backers of Precision BioSciences, Inc. include Aberdeen Group plc, Bleichroeder LP, Octagon Capital Advisors LP, according to Nexqual as of November 10, 2026 at 04:58 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, November 10, 2026 at 04:58 UTC.

From Precision BioSciences, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)

Key Strengths & Strategy (as disclosed to the SEC)

• Recently, iECURE reached alignment with the FDA on the primary and key secondary efficacy endpoints, comparators and study size for the ongoing OTC-HOPE study which could support a Biologics License Application.
• We seek to protect our proprietary technology and processes, in part, by monitoring confidential disclosures and through confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors and others who may have access to proprietary information, under which they are bound to assign to us inventions made during the term of their employment or term of service.
• We also rely on trademarks, trade secrets, know-how, continuing technological innovation and confidential information, and the pursuit of licensing opportunities, to develop and maintain our proprietary position and protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection.
• We cannot be sure that patents will be granted with respect to any patent applications we have licensed or filed or may license or file in the future, and we cannot be sure that any patents we have licensed or which have been granted to us, or patents that may be licensed or granted to us in the future, will not be challenged, invalidated or circumvented or that such patents will be commercially useful in protecting our technology.

Partnerships

• In partnership with iECURE, Inc. ("iECURE"), an ARCUS-mediated targeted gene insertion approach, ECUR-506, is being evaluated as a potential curative treatment option for neonatal onset ornithine transcarbamylase ("OTC") deficiency.
• In connection with the iECURE DLA, we and iECURE entered into an equity issuance agreement (the "iECURE Equity Agreement"), pursuant to which iECURE issued us common stock in iECURE as additional consideration for the license to use our PCSK9-directed ARCUS nuclease.

Legal & Regulatory Risks (Item 1A, quoted)

• We face significant competition in industries experiencing rapid technological change, and there is a possibility that our competitors may achieve regulatory approval before us or develop product candidates or treatments that are safer or more effective than ours, which may harm our financial condition and our ability to successfully market or commercialize any of our product candidates.
• Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any products that we develop alone or with collaborators.
• The regulatory landscape that will apply to development of therapeutic product candidates by us or our collaborators is rigorous, complex, uncertain and subject to change, which could result in delays or termination of development of such product candidates or unexpected costs in obtaining regulatory approvals.
• Any delays or difficulties in our or our collaborators' ability to enroll patients in clinical trials could delay or prevent receipt of regulatory approvals.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: November 10, 2026 at 04:58 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt